Skip to main content
Top
Published in: International Journal of Hematology 1/2008

01-07-2008 | Images in Hematology

Disseminated diffuse large B cell lymphoma of bone on PET scan

Authors: Wei-Liang Chen, Ching-Liang Ho

Published in: International Journal of Hematology | Issue 1/2008

Login to get access

Excerpt

On January 2006, a 33-year-old previously-healthy male was admitted to the hospital with a three-year history of intermittent low back pain and radiating to bilateral lower legs along anterior thighs. Physical examination revealed weakness of bilateral legs with paresthesias and diminished deep tendon reflex. Physically, there was neither hepatosplenomegaly nor lymphadenopathy. There was no illicit drug use, exposure to environmental toxins, recent traveling or traumatic history. His family history was noncontributory. Magnetic resonance image of spine (Fig. 1) showed diffuse heterogeneous enhancing lesions over whole spine including cervical, thoracic, and lumbar spines. The histopathology of bone marrow biopsy (Fig. 2) revealed diffuse large B cell lymphoma with positive for CD20. A staging 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) (Fig. 3) demonstrated disseminated 18F-FDG uptake lesions over the bone of whole body, including skull, whole spines, pelvis, upper limbs and lower limbs. The liver and spleen also showed multiple lesions. He received eight courses of chemotherapy with rituximab, cyclophosphamide, adriamycin, oncovin and prednisolone (R-CHOP), followed by high-dose chemotherapy combined with autologous peripheral blood stem cell transplantation. The following PET scan (Fig. 4) showed no evidence of abnormal FDG uptake throughout whole body region. The patient remained in complete remission at 10 months.
Metadata
Title
Disseminated diffuse large B cell lymphoma of bone on PET scan
Authors
Wei-Liang Chen
Ching-Liang Ho
Publication date
01-07-2008
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0097-0

Other articles of this Issue 1/2008

International Journal of Hematology 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine